Empagliflozin is used to lower blood sugar levels in adults with type 2 diabetes who have failed to achieve control by diet and exercise alone.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Jardiance 25 mg Tablet contains Empagliflozin, categorized as an anti-diabetic drug. It is utilized for the management of type 2 diabetes in adults when diet and exercise alone are insufficient. Additionally, it aids in reducing the risk of heart disease in individuals with type 2 diabetes and is employed in the treatment of heart failure in adults with weakened heart pumping function.
Before starting Jardiance 25 mg Tablet, undergo necessary blood tests as recommended by your doctor. Adhere to dietary and exercise advice provided. Keep your doctor informed about your health condition for optimal diabetes and heart management.
Taking Empagliflozin with alcohol may affect blood glucose levels in patients with diabetes.
The use of Jardiance 25 mg Tablet is not recommended during pregnancy due to the potential harm it may cause to the developing fetus. If you are pregnant or planning to become pregnant, consult with your doctor. Your healthcare provider will assess the potential benefits and risks before considering the prescription of this medicine during pregnancy.
It is unclear whether Jardiance 25 mg Tablet passes into breast milk. Therefore, if you are breastfeeding, consult your doctor before taking this medication. Your healthcare provider will provide guidance based on the potential risks and benefits, helping you make an informed decision about whether to use this medicine while breastfeeding.
Do not drive or operate any machines if you feel dizzy after taking Jardiance 25 mg Tablet.
Jardiance 25 mg Tablet should be taken with caution in patients with severe kidney disease and serious infection of the kidney. Consult your doctor before taking it.
Jardiance 25 mg Tablet should be used with caution in patients with severe liver disease. Consult your doctor before taking it.
Common Side Effects:
Uncommon/Rare Side Effects:
Emergency Situations: Cease Jardiance 25 mg Tablet and seek immediate medical attention for severe allergic reactions or diabetic ketoacidosis symptoms.
It is used to:
Empagliflozin is indeed an inhibitor of the sodium-glucose co-transporter-2 (SGLT-2). This class of medications, known as SGLT-2 inhibitors, primarily targets the SGLT2 co-transporters in the kidneys. These co-transporters play a crucial role in the reabsorption of glucose from the glomerular filtrate in the kidney.
By inhibiting SGLT-2, empagliflozin promotes glucuretic action. This means that it reduces the reabsorption of glucose by the kidneys, leading to increased glucose excretion in the urine. This process effectively lowers the renal glucose threshold, resulting in higher levels of glucose being expelled from the body through urine. By doing so, empagliflozin helps lower blood glucose levels, making it an effective medication for managing hyperglycemia in people with diabetes.
Additionally, the glucuretic action of empagliflozin can contribute to weight loss, as the body expels excess glucose calories through urine. Furthermore, the medication has been associated with lowering blood pressure, providing additional cardiovascular benefits for individuals with diabetes.
In summary, empagliflozin's mechanism of action involves inhibiting SGLT-2, leading to increased urinary excretion of glucose, weight loss, and beneficial effects on blood pressure, all contributing to the management of hyperglycemia in individuals with diabetes.
Follow your physician's advice when takingJardiance 25. Swallow the tablet with a glass of water without crushing or chewing. The appropriate dose and duration will be determined by your doctor based on factors such as age, body weight, and medical condition. Do not discontinue the medication unless advised by your doctor.
Discuss with your doctor if taking diuretics or sulphonylureas.
Patients having a history of serious allergic reactions to Empagliflozin or any of its constituents, severe renal impairment, end-stage renal disease, or dialysis should not take Empagliflozin.
Assessment of renal function is recommended before initiation of Empagliflozin and periodically thereafter. Empagliflozin should not initiated in patients with an eGFR less than 45 ml/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.
Keep away from light and moisture in a cool, dry location (below 30° C). Keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.